Insider · CIK 0001263965
Yuichi Iwaki
Files at MNOV (MEDICINOVA INC). First filing -, latest -.
In brief
Yuichi Iwaki files SEC Form 4 as CEO, president and director at MNOV (MEDICINOVA INC). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Yuichi Iwaki has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 16, 2026 | MNOV MEDICINOVA INC | AGrant or award Employee Stock Option (Right to Buy)derivative | +450,000 | $0.00 | $0 | 450,000 | Jan 20, 2026 |
| Feb 12, 2025 | MNOV MEDICINOVA INC | AGrant or award Employee Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Feb 14, 2025 |
| Jan 7, 2025 | MNOV MEDICINOVA INC | AGrant or award Employee Stock Option (Right to Buy)derivative | +400,000 | $0.00 | $0 | 400,000 | Jan 10, 2025 |
| Jan 9, 2024 | MNOV MEDICINOVA INC | AGrant or award Employee Stock Option (Right to Buy)derivative | +210,000 | $0.00 | $0 | 210,000 | Jan 11, 2024 |
Questions about Yuichi Iwaki
Answered from the filings on this page, as of the latest one.
Is Yuichi Iwaki buying or selling?
Yuichi Iwaki has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Yuichi Iwaki's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Yuichi Iwaki has 0.
Where does Yuichi Iwaki file Form 4?
Yuichi Iwaki has filed Form 4 at MNOV (MEDICINOVA INC) as President and CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.